These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26603212)

  • 41. Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer.
    Chang Y; Funk M; Roy S; Stephenson E; Choi S; Kojouharov HV; Chen B; Pan Z
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combinations of targeted therapies in human cancers.
    Decaudin D; Le Tourneau C
    Aging (Albany NY); 2016 Oct; 8(10):2258-2259. PubMed ID: 27783563
    [No Abstract]   [Full Text] [Related]  

  • 43. Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
    Bashi AC; Coker EA; Bulusu KC; Jaaks P; Crafter C; Lightfoot H; Milo M; McCarten K; Jenkins DF; van der Meer D; Lynch JT; Barthorpe S; Andersen CL; Barry ST; Beck A; Cidado J; Gordon JA; Hall C; Hall J; Mali I; Mironenko T; Mongeon K; Morris J; Richardson L; Smith PD; Tavana O; Tolley C; Thomas F; Willis BS; Yang W; O'Connor MJ; McDermott U; Critchlow SE; Drew L; Fawell SE; Mettetal JT; Garnett MJ
    Cancer Discov; 2024 May; 14(5):846-865. PubMed ID: 38456804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come.
    Scarlett UK; Chang DC; Murtagh TJ; Flaherty KT
    Cancer Discov; 2016 Sep; 6(9):956-62. PubMed ID: 27587468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.
    Emmons MF; Faião-Flores F; Smalley KSM
    Biochem Pharmacol; 2016 Dec; 122():1-9. PubMed ID: 27349985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correction: GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725217
    [No Abstract]   [Full Text] [Related]  

  • 47. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
    Schuler M; Yang JC; Park K; Kim JH; Bennouna J; Chen YM; Chouaid C; De Marinis F; Feng JF; Grossi F; Kim DW; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand VK; Planchard D;
    Ann Oncol; 2016 Mar; 27(3):417-23. PubMed ID: 26646759
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
    Watanabe S; Inoue A; Nukiwa T; Kobayashi K
    Anticancer Res; 2015 Dec; 35(12):6957-61. PubMed ID: 26637922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genomic classification of lung cancer: toward a personalized treatment.
    Mlika M; Laabidi S; Afrit M; Boussen H; El Mezni F
    Tunis Med; 2015 Jun; 93(6):339-44. PubMed ID: 26644092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
    Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
    Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of advanced squamous cell carcinoma of the lung: a review.
    Derman BA; Mileham KF; Bonomi PD; Batus M; Fidler MJ
    Transl Lung Cancer Res; 2015 Oct; 4(5):524-32. PubMed ID: 26629421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
    Lee JY; Sun JM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Ku BM; Koh J; Bae YH; Lee SH; Ahn JS; Park K; Ahn MJ
    Clin Cancer Res; 2016 May; 22(9):2139-45. PubMed ID: 26667485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical development of nintedanib for advanced non-small-cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Ther Clin Risk Manag; 2015; 11():1701-6. PubMed ID: 26622180
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Second-line combination therapies in nonsmall cell lung cancer without known driver mutations.
    Bluthgen MV; Besse B
    Eur Respir Rev; 2015 Dec; 24(138):582-93. PubMed ID: 26621972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
    Chen KL; Lin CC; Cho YT; Yang CW; Sheen YS; Tsai HE; Chu CY
    JAMA Dermatol; 2016 Mar; 152(3):340-2. PubMed ID: 26649681
    [No Abstract]   [Full Text] [Related]  

  • 57. A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
    Gómez HL; Neciosup S; Tosello C; Mano M; Bines J; Ismael G; Santi PX; Pinczowski H; Nerón Y; Fanelli M; Fein L; Sampaio C; Lerzo G; Capó A; Zarba JJ; Blajman C; Varela MS; Martínez-Mesa J; Werutsky G; Barrios CH
    Clin Breast Cancer; 2016 Feb; 16(1):38-44. PubMed ID: 26642810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.
    Park HS; Lim SM; Shin HJ; Cho A; Shin JG; Lee MG; Kim HR; Kim JH; Cho BC
    Pharmacogenet Genomics; 2016 Mar; 26(3):116-25. PubMed ID: 26641474
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
    Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Viteri S; González-Cao M; Morales-Espinosa D; Verlicchi A; Crisetti E; Chaib I; Santarpia M; Luis Ramírez J; Bosch-Barrera J; Felipe Cardona A; de Marinis F; López-Vivanco G; Miguel Sánchez J; Vergnenegre A; Sánchez Hernández JJ; Sperduti I; Bria E; Rosell R
    Sci Rep; 2015 Dec; 5():17499. PubMed ID: 26639561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PROFILE 1014: lessons for the new era of lung cancer clinical research.
    Noonan SA; Camidge DR
    Transl Lung Cancer Res; 2015 Oct; 4(5):642-8. PubMed ID: 26629438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.